## **Core Concept**
Neutropenia, a condition characterized by an abnormally low number of neutrophils, is a common side effect of cancer chemotherapy. It increases the risk of infections. The management of neutropenia involves the use of hematopoietic growth factors to stimulate the production of neutrophils.

## **Why the Correct Answer is Right**
The correct answer, **Filgrastim**, is a recombinant DNA-derived human granulocyte colony-stimulating factor (G-CSF). G-CSF stimulates the bone marrow to produce more neutrophils, thereby reducing the risk of infection in patients with neutropenia. Filgrastim is widely used for this purpose due to its efficacy in rapidly increasing neutrophil counts.

## **Why Each Wrong Option is Incorrect**
- **Option A: Erythropoietin** - This is incorrect because erythropoietin is used to stimulate red blood cell production, not neutrophil production. It is primarily used to treat anemia, another side effect of chemotherapy.
- **Option B: Interleukin-2** - This is incorrect because interleukin-2 (IL-2) is a type of cytokine that primarily stimulates the proliferation of T cells, not neutrophils. It is used in immunotherapy for certain cancers but not for treating neutropenia.
- **Option D: Iron supplements** - This is incorrect because iron supplements are used to treat iron deficiency anemia, not neutropenia. They have no effect on neutrophil production.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **Filgrastim (G-CSF)** is the drug of choice for managing neutropenia caused by cancer chemotherapy. It works by stimulating the bone marrow to produce more neutrophils, thus helping to prevent infections in these patients.

## **Correct Answer:** . Filgrastim